Cheng Xin / Getty Images Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped. The biotech firm also posted a decline in sales outside the U.S. because of ...

Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue while reporting a separate impairment charge of $379 million tied to an earlier ...

You can reach Jason on Signal at JasonMast.05. Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic ...

Amid the launch of its non-opioid pain med Journavx, Vertex Pharmaceuticals has begun an awareness-raising blitz focused on acute pain management. The new campaign stars former NFL quarterback ...

Vertex Pharmaceuticals misses analyst estimates on the top and bottom lines in the first quarter. Vertex raises its full-year 2025 revenue guidance to a range of $11.85 billion to $12 billion ...

Vertex Pharmaceuticals VRTX will release its quarterly earnings report on Monday, 2025-05-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Vertex ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results tomorrow afternoon. Here’s what investors should know. Vertex Pharmaceuticals beat analysts’ revenue ...

Non-GAAP Effective Tax Rate: 18.8% for Q1 2025. Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported a 3% year-over-year revenue growth, reaching $2.77 billion in Q1 2025. The company successfully ...

Vertex Minerals chair Roger Jackson says he is confident the explorer is on the cusp of significant cash generation, as it moves toward production at its Hill End gold project in NSW. “This capital ...

Solar financing platform Metafin on Tuesday said it raised $10 million in a Series A funding round led by Vertex Ventures Southeast Asia and India. The round, a mix of equity and debt, also saw ...